Cancer Immunotherapy News and Research

RSS

New ERC-funded research project aims to develop targeted treatments for chronic wounds and cancer

the Freiburg University Medical Center and member of the Medical Faculty at the University of Freiburg, has received a European Research Council (ERC) Starting Grant from the European Commission.

27 Oct 2023

Microbubble-based biomarker could improve NIR-PIT treatment for cancer

Researchers at Nagoya University in Japan and their collaborators have used a biomarker based on microbubbles to evaluate the success of near-infrared photoimmunotherapy (NIR-PIT) treatment.

26 Oct 2023

New bioreactor could accelerate access to cancer-killing immunotherapy

A new tool to rapidly grow cancer-killing white blood cells could advance the availability of immunotherapy, a promising therapy which harnesses the power of the body's immune response to target cancer cells.

26 Oct 2023

Could the microbiome hold the key to diagnosing and treating biliary tract cancer?

A recent study in "Microorganisms" delves into the relationship between the microbiome and biliary tract cancer, revealing distinct microbial compositions in patients compared to healthy individuals. This research highlights potential diagnostic biomarkers and suggests that altering gut microbial composition might enhance responses to cancer immunotherapy.

24 Oct 2023

Utilizing Biomarkers in Cancer Prevention, Diagnosis, and Treatment

In this interview, Grace Liu from Sino Biological discusses the crucial role of biomarkers in cancer prevention and diagnosis and how they can help guide treatment decisions.

From Sino Biological Inc. 24 Oct 2023

"Two-for-one" cancer immunotherapy more effective and at least as safe as standard treatments

A "two-for-one" cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial report today in the journal Nature Medicine.

19 Oct 2023

Insilico Medicine to present scientific data on novel anti-cancer assets at major cancer conferences

Clinical stage artificial intelligence (AI) drug discovery company Insilico Medicine ("Insilico") has been invited to present scientific data on its novel anti-cancer assets at three major upcoming cancer conferences -- the European Society for Medical Oncology (ESMO) conference in Madrid Oct. 20-24, 2023; the Society of Immunotherapy of Cancer (SITC) conference Nov. 1-5, 2023 in San Diego; and the San Antonio Breast Cancer Symposium (SABCS) Dec. 5-9, 2023.

16 Oct 2023

Cracking the code: recent discoveries transform our understanding of cancer-immunity cycle

In a recent review published in Immunity, researchers reviewed tumor-immunity cycle data.

13 Oct 2023

Engineered bacteria deliver synthetic targets to solid tumors

For several years, researchers have been successfully using chimeric antigen receptor (CAR) T cells to target specific antigens found on blood cells as a cure for patients with leukemia and lymphoma.

12 Oct 2023

New nanocapsule treatment boosts immune response against solid tumors

UCLA researchers have developed a new treatment method using a tiny nanocapsule to help boost the immune response, making it easier for the immune system to fight and kill solid tumors.

11 Oct 2023

Liquid biopsies could be used as an early marker of immunotherapy response, study finds

Liquid biopsies are blood tests that can serially measure circulating tumor DNA (cell-free DNA that is shed into the bloodstream by dying cancer cells).

9 Oct 2023

Targeting Microbiota 2023 captures the essence of microbiota research and future implications

Targeting Microbiota 2023 will be a ground-breaking experience that will introduce you to the latest advancements in the microbiota field.

9 Oct 2023

New computational method improves analysis of single-cell transcriptomic data

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed a new open-source computational method, dubbed Spectra, which improves the analysis of single-cell transcriptomic data.

5 Oct 2023

Unlocking the future of cancer care: Overcoming challenges in personalized neoantigen vaccine development

Challenges associated with the development and design of neoantigen cancer vaccines.

5 Oct 2023

Research opens the door for better use of people's own immune system T cells to fight cancer

Using laboratory-grown cells from humans and genetically engineered mice, scientists at Johns Hopkins Medicine say they have evidence that modifying a specific protein in immune white blood cells known as CD8+ T cells can make the cells more robust, potentially opening the door for better use of people's own immune system T cells to fight cancer.

3 Oct 2023

Neoadjuvant immunotherapy shows promise in multiple cancer types

Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly growing area of research, but the scientific community is just scratching the surface of what is possible, according to a review article co-authored by several current and former investigators from the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Kimmel Cancer Center.

28 Sep 2023

$45M awarded to develop sense-and-respond implant technology for cancer treatment

The Advanced Research Projects Agency for Health (ARPA-H) has awarded $45 million to rapidly develop sense-and-respond implant technology that could slash U.S. cancer-related deaths by more than 50%.

26 Sep 2023

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.

21 Sep 2023

Unlocking the secret soldiers: How dendritic cells could revolutionize cancer immunotherapy

A recent review in the journal Immunity delves into the crucial role of dendritic cells (DCs) in shaping T-cell responses in cancer, highlighting their importance in both priming anti-tumor immunity and in ongoing immune interactions within tumors. The findings underscore the potential of DCs as key targets for next-generation cancer immunotherapies.

18 Sep 2023

New trial shows promise of combination neoadjuvant immunotherapy for lung cancer

Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.

14 Sep 2023